CompletedPhase 4

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

United States104 participantsStarted 2018-03-08

Plain-language summary

This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years
✓. Previous CDI diagnosis
✓. Current admission with a suspected or a confirmed bacterial infection requiring antibiotics

Exclusion criteria

✕. Active chronic diarrheal illness (eg, Crohn's disease, ulcerative colitis, short bowel syndrome)
✕. Previous adverse reactions to oral vancomycin
✕. Requiring metronidazole during hospitalization
✕. Known pregnancy
✕. Expected survival \<72 hours
✕. Patients receiving antibiotics only for surgical prophylaxis
✕. Patients who received prophylactic oral vancomycin for the current antibiotic course prior to enrollment in the study

What they're measuring

Recurrent Clostridium difficile infection

Timeframe: During hospitalization or the 12 weeks after therapy

Trial details

NCT IDNCT03466502

SponsorUniversity of Nevada, Reno

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-17

View on ClinicalTrials.gov More Clostridium Difficile Infection trials